X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (404) 404
Book Review (97) 97
Publication (16) 16
Book Chapter (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
linagliptin (351) 351
index medicus (309) 309
humans (271) 271
diabetes mellitus, type 2 - drug therapy (223) 223
type 2 diabetes (187) 187
male (180) 180
dipeptidyl-peptidase iv inhibitors - therapeutic use (176) 176
hypoglycemic agents - therapeutic use (151) 151
female (143) 143
diabetes (141) 141
endocrinology & metabolism (136) 136
double-blind (110) 110
middle aged (110) 110
pharmacology & pharmacy (107) 107
aged (103) 103
dipeptidyl peptidase-4 inhibitor (98) 98
metformin (96) 96
sitagliptin (96) 96
glucose (93) 93
quinazolines - therapeutic use (92) 92
treatment outcome (92) 92
purines - therapeutic use (91) 91
animals (86) 86
dpp-4 inhibitor (86) 86
dipeptidyl-peptidase iv inhibitors - adverse effects (84) 84
glycemic control (82) 82
linagliptin - therapeutic use (79) 79
diabetes mellitus, type 2 - blood (78) 78
dipeptidyl-peptidase iv inhibitors - pharmacology (78) 78
safety (72) 72
hypoglycemic agents - adverse effects (66) 66
vildagliptin (66) 66
glucagon-like peptide-1 (64) 64
adult (61) 61
type 2 diabetes mellitus (60) 60
double-blind method (58) 58
blood glucose - drug effects (57) 57
analysis (56) 56
pharmacokinetics (56) 56
drug therapy (55) 55
efficacy (55) 55
diabetes mellitus (53) 53
dipeptidyl peptidase-4 inhibitors (53) 53
risk factors (52) 52
saxagliptin (52) 52
care and treatment (50) 50
dipeptidyl-peptidase iv inhibitors - administration & dosage (50) 50
drug therapy, combination (50) 50
hypoglycemic agents (49) 49
blood glucose - metabolism (48) 48
hypoglycemic agents - administration & dosage (48) 48
hypoglycemic agents - pharmacology (48) 48
type-2 diabetes-mellitus (48) 48
clinical trials (47) 47
dextrose (46) 46
internal medicine (46) 46
diabetes therapy (45) 45
glycated hemoglobin a - metabolism (45) 45
mellitus (45) 45
metformin - therapeutic use (43) 43
dosage and administration (42) 42
purines - adverse effects (42) 42
quinazolines - adverse effects (42) 42
quinazolines - pharmacology (42) 42
research (42) 42
purines - pharmacology (41) 41
rats (41) 41
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (40) 40
hypoglycemia (39) 39
purines - administration & dosage (39) 39
quinazolines - administration & dosage (39) 39
bi 1356 (38) 38
diabetes mellitus, type 2 - complications (38) 38
dpp-4 inhibitors (38) 38
peptidase (38) 38
add-on therapy (37) 37
randomized controlled trials as topic (37) 37
dipeptidyl peptidase 4 - metabolism (36) 36
alogliptin (35) 35
beta-cell function (35) 35
linagliptin - pharmacology (34) 34
glycosylated hemoglobin (33) 33
insulin (33) 33
linagliptin - adverse effects (33) 33
hyperglycemia (32) 32
improves glycemic control (32) 32
mice (32) 32
medicine, general & internal (31) 31
pharmacodynamics (31) 31
tolerability (31) 31
aged, 80 and over (30) 30
medicine & public health (30) 30
oxidative stress (30) 30
abridged index medicus (29) 29
adamantane - analogs & derivatives (29) 29
hypoglycemia - chemically induced (29) 29
medicine, research & experimental (29) 29
renal impairment (29) 29
cardiac & cardiovascular systems (28) 28
complications and side effects (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9840, pp. 475 - 483
Summary Background Addition of a sulphonylurea to metformin improves glycaemic control in type 2 diabetes, but is associated with hypoglycaemia and weight... 
Internal Medicine | ALL-CAUSE MORTALITY | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | ADD-ON | METAANALYSIS | SULFONYLUREA | GLUCOSE CONTROL | CARDIOVASCULAR-DISEASE | RISK | COMPLICATIONS | MELLITUS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Purines - administration & dosage | Hypoglycemic Agents - administration & dosage | Treatment Failure | Adult | Female | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Sulfonylurea Compounds - administration & dosage | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Research Design | Type 2 diabetes | Complications and side effects | Dosage and administration | Metformin | Drug therapy | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Glimepiride | Comparative analysis | Heart attacks | Diabetes | Pharmaceutical industry | Drug dosages | Index Medicus | Abridged Index Medicus | Drugs | Obesity | Body weight | Diabetes mellitus
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, pp. e0135634 - e0135634
Aim Unlike rats and mice, hamsters develop hypercholesterolemia, and hypertriglyceridemia when fed a cholesterol-rich diet. Because hyperlipidemia is a... 
CHOLESTEROL ABSORPTION | BODY-WEIGHT | TRANSFER PROTEIN | METABOLIC SYNDROME | GLUCAGON-LIKE PEPTIDE-1 | NEUROMEDIN U | FOOD-INTAKE | GLUCOSE | MULTIDISCIPLINARY SCIENCES | IV INHIBITOR | RECEPTOR | Hypoglycemic Agents - therapeutic use | Cricetinae | Obesity - drug therapy | Cholesterol - blood | Diet, High-Fat - adverse effects | Male | Linagliptin - therapeutic use | Obesity - blood | Anti-Obesity Agents - therapeutic use | Neuropeptides - therapeutic use | Blood Glucose - drug effects | Eating - drug effects | Animals | Anticholesteremic Agents - therapeutic use | Mesocricetus | Peptide YY - therapeutic use | Obesity - etiology | Ezetimibe - therapeutic use | Hypolipidemic Agents - therapeutic use | Peptide Fragments - therapeutic use | Low density lipoproteins | Body weight | Glucose | Hamsters | Cholesterol | Dextrose | Antilipemic agents | Hypercholesterolemia | Diet therapy | Diet | Analysis | Blood lipids | Diabetes | Lipoproteins (low density) | Neurosciences | Peptides | Body fat | Lipids | Metabolic syndrome | Rodents | Supplementation | Lipoproteins (high density) | Sugar | Food | Energy intake | Obesity | Evaluation | Peptidase | Hyperlipidemia | Diabetes mellitus | Dietary supplements | Apolipoproteins | Body weight gain | Glucose tolerance | Weight control | Lipoproteins | Inhibitors | Food intake | Hypertriglyceridemia | Weight reduction | Food preferences | Insulin resistance | Laboratory animals | Endocrinology | Neuromedin | Index Medicus
Journal Article
Diabetes, ISSN 0012-1797, 04/2013, Volume 62, Issue 4, pp. 1289 - 1296
Journal Article
Kidney and Blood Pressure Research, ISSN 1420-4096, 02/2013, Volume 36, Issue 1, pp. 119 - 130
Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor... 
Original Paper | Diabetic nephropathy | Linagliptin | Renin-angiotensin system | DPP-4 inhibitor | OXIDATIVE STRESS | PHYSIOLOGY | NITRIC-OXIDE SYNTHASE | GLOMERULAR-LESIONS | KNOCKOUT MICE | GENE POLYMORPHISM | DIPEPTIDYL PEPTIDASE-4 | HEALTHY MALE-VOLUNTEERS | DISEASE | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | PERIPHERAL VASCULAR DISEASE | RENAL REPLACEMENT THERAPY | Dipeptidyl Peptidase 4 - drug effects | Benzoates - therapeutic use | Diabetic Nephropathies - etiology | Oxidative Stress - physiology | Angiotensin Receptor Antagonists - pharmacology | Diabetic Nephropathies - drug therapy | Male | Nitric Oxide Synthase Type III - deficiency | Diabetic Nephropathies - physiopathology | Nitric Oxide Synthase Type III - physiology | Blood Pressure - drug effects | Blood Pressure - physiology | Diabetes Mellitus, Experimental - chemically induced | Diabetes Mellitus, Experimental - complications | Purines - therapeutic use | Drug Therapy, Combination | Streptozocin - adverse effects | Benzimidazoles - therapeutic use | Disease Models, Animal | Purines - pharmacology | Mice, Inbred C57BL | Enzyme Inhibitors - pharmacology | Treatment Outcome | Enzyme Inhibitors - therapeutic use | Nitric Oxide Synthase Type III - genetics | Mice, Knockout | Dipeptidyl Peptidase 4 - physiology | Animals | Quinazolines - therapeutic use | Benzoates - pharmacology | Benzimidazoles - pharmacology | Mice | Oxidative Stress - drug effects | Quinazolines - pharmacology | Angiotensin Receptor Antagonists - therapeutic use | Index Medicus
Journal Article
Diabetic Medicine, ISSN 0742-3071, 11/2011, Volume 28, Issue 11, pp. 1352 - 1361
Aims To examine the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in persons with Type 2 diabetes mellitus inadequately controlled... 
metformin | linagliptin | dipeptidyl peptidase‐4 inhibitor | sulphonylurea | Type 2 diabetes | Type 2 diabetes | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-4 INHIBITOR | CONSENSUS | dipeptidyl peptidase-4 inhibitor | PHARMACODYNAMICS | MELLITUS | BETA-CELL FUNCTION | ADD-ON THERAPY | PHARMACOKINETICS | ENDOCRINOLOGY & METABOLISM | BI 1356 | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Purines - administration & dosage | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Purines - therapeutic use | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Drug Therapy, Combination | Body Mass Index | Hypoglycemic Agents - therapeutic use | Fasting | Double-Blind Method | Treatment Outcome | Biomarkers - blood | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - blood | Quinazolines - therapeutic use | Adolescent | Quinazolines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Analysis | Hypoglycemic agents | Glucose | Diabetes | Research | Dextrose | Diabetes therapy | Index Medicus
Journal Article
Diabetes & vascular disease research, ISSN 1479-1641, 2015, Volume 12, Issue 3, pp. 164 - 174
Journal Article